Treatment of corneal defects with delayed re-epithelization with a medical device/drug delivery system for epidermal growth factor

Clinical and Experimental Ophthalmology

Volumn 40, Issue 7, 2012, Pages 662-668

  Holland, Simon ^a,b   Morck, Douglas ^c   Schultz, Clyde ^c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Vancouver General Hospital Eye Care Centre   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d DirectContact LLC   (United States)

Author keywords

Bandage contact lens; Cornea; Epidermal growth factor; Epithelial defect; Wound healing

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; DEXAMETHASONE; FLUOROMETHOLONE; GATIFLOXACIN; KETOROLAC TROMETAMOL; MOXIFLOXACIN; OFLOXACIN; PREDNISOLONE ACETATE; PREDNISOLONE SODIUM PHOSPHATE; RECOMBINANT EPIDERMAL GROWTH FACTOR; TOBRAMYCIN;

ADULT; AGED; ARTICLE; BANDAGE CONTACT LENS; CLINICAL ARTICLE; CONTACT LENS; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA ULCER; CORNEAL DEFECT; DESCEMET MEMBRANE; DRUG DELIVERY SYSTEM; DRY EYE; FEMALE; FOLLOW UP; HUMAN; KERATECTOMY; PENETRATING KERATOPLASTY; PROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TERTIARY HEALTH CARE; TRICHIASIS; VISUAL ACUITY;

ADOLESCENT; AGED; CONTACT LENSES, HYDROPHILIC; CORNEAL DISEASES; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; EPITHELIUM, CORNEAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RE-EPITHELIALIZATION; VISUAL ACUITY; WOUND HEALING; YOUNG ADULT;

EID: 84867395843     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02795.x     Document Type: Article

References (23)

1. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979; 48: 193-216.
2. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001; 72: 511-17.
3. Wilson SE, Chen L, Mohan RR, Liang Q, Liu J. Expression of HGF, KGF, EGF and receptor messenger RNAs following corneal epithelial wounding. Exp Eye Res 1999; 68: 377-97.
4. Wilson SE, Schultz GS, Chegini N, Weng J, He YG. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea. Exp Eye Res 1994; 59: 63-71.
5. Ohashi Y, Motokura M, Kinoshita Y etal. Presence of epidermal growth factor in human tears. Invest Ophthalmol Vis Sci 1989; 30: 1879-82.
6. van Setten GB, Viinikka L, Tervo T, Pesonen K, Tarkkanen A, Perheentupa J. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol 1989; 227: 184-7.
7. Klenkler B, Sheardown H, Jones L. Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology. Ocul Surf 2007; 5: 228-39.
8. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res 2004; 79: 677-88.
9. Kim MJ, Jun RM, Kim WK etal. Optimal concentration of human epidermal growth factor (hEGF) for epithelial healing in experimental corneal alkali wounds. Curr Eye Res 2001; 22: 272-9.
10. Brazzell RK, Stern ME, Aquavella JV, Beuerman RW, Baird L. Human recombinant epidermal growth factor in experimental corneal wound healing. Invest Ophthalmol Vis Sci 1991; 32: 336-40.
11. Kitazawa T, Kinoshita S, Fujita K etal. The mechanism of accelerated corneal epithelial healing by human epidermal growth factor. Invest Ophthalmol Vis Sci 1990; 31: 1773-8.
12. Forster CG, Cursiefen C, Kruse FE. [Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment]. Ophthalmologe 2008; 105: 269-73.
13. He J, Bazan HE. Epidermal growth factor synergism with TGF-beta1 via PI-3 kinase activity in corneal keratocyte differentiation. Invest Ophthalmol Vis Sci 2008; 49: 2936-45.
14. Dellaert MM, Casey TA, Wiffen S etal. Influence of topical human epidermal growth factor on postkeratoplasty re-epithelialisation. Br J Ophthalmol 1997; 81: 391-5.
15. Xinming L, Yingde C, Lloyd AW etal. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review. Cont Lens Anterior Eye 2008; 31: 57-64.
16. Schultz CL, Poling TR, Mint JO. A medical device/drug delivery system for treatment of glaucoma. Clin Exp Optom 2009; 92: 343-8.
17. Schultz CL, Morck DW. Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Clin Exp Optom 2010; 93: 61-65.
18. Lauffenburger DA, Linderman JJ. Receptors: Models for Binding, Trafficking, and Signaling. New York: Oxford University Press, 1993.
19. Nezu E, Ohashi Y, Kinoshita S, Manabe R. Recombinant human epidermal growth factor and corneal neovascularization. Jpn J Ophthalmol 1992; 36: 401-6.
20. Chung JH, Fagerholm P. Treatment of rabbit corneal alkali wounds with human epidermal growth factor. Cornea 1989; 8: 122-8.
21. Sakamoto T, Ueno H, Sonoda K etal. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Ther 2000; 7: 1915-24.
22. Kokawa N, Sotozono C, Nishida K, Kinoshita S. High total TGF-beta 2 levels in normal human tears. Curr Eye Res 1996; 15: 341-3.
23. Márquez EB, Ortueta DD, Royo SB, Martínez-Carpio PA. Epidermal growth factor receptor in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol 2011; 30: 7-14.